Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Sees Significant Growth in Short Interest

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) was the recipient of a significant increase in short interest in December. As of December 31st, there was short interest totaling 5,532,159 shares, an increase of 32.2% from the December 15th total of 4,184,652 shares. Based on an average trading volume of 1,911,674 shares, the days-to-cover ratio is presently 2.9 days. Approximately 4.2% of the shares of the stock are short sold. Approximately 4.2% of the shares of the stock are short sold. Based on an average trading volume of 1,911,674 shares, the days-to-cover ratio is presently 2.9 days.

Alnylam Pharmaceuticals Trading Up 0.0%

NASDAQ ALNY opened at $359.27 on Friday. The company has a current ratio of 2.54, a quick ratio of 2.49 and a debt-to-equity ratio of 4.45. Alnylam Pharmaceuticals has a 1-year low of $205.87 and a 1-year high of $495.55. The firm’s fifty day simple moving average is $418.74 and its 200-day simple moving average is $422.05. The company has a market capitalization of $47.46 billion, a PE ratio of 1,496.96 and a beta of 0.32.

Insider Activity at Alnylam Pharmaceuticals

In other news, EVP Tolga Tanguler sold 1,510 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $362.87, for a total value of $547,933.70. Following the transaction, the executive vice president owned 29,728 shares of the company’s stock, valued at $10,787,399.36. The trade was a 4.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Yvonne Greenstreet sold 15,650 shares of the stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $453.69, for a total transaction of $7,100,248.50. Following the sale, the chief executive officer directly owned 65,409 shares of the company’s stock, valued at approximately $29,675,409.21. This represents a 19.31% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 56,955 shares of company stock worth $24,072,733. Company insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Several hedge funds have recently bought and sold shares of ALNY. Vanguard Group Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 2.0% during the 3rd quarter. Vanguard Group Inc. now owns 13,565,452 shares of the biopharmaceutical company’s stock valued at $6,185,846,000 after acquiring an additional 268,313 shares during the last quarter. Capital Research Global Investors boosted its position in Alnylam Pharmaceuticals by 0.4% during the third quarter. Capital Research Global Investors now owns 7,222,840 shares of the biopharmaceutical company’s stock worth $3,293,516,000 after purchasing an additional 31,184 shares during the period. Groupama Asset Managment grew its holdings in Alnylam Pharmaceuticals by 160.4% during the third quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company’s stock valued at $18,610,000 after purchasing an additional 2,483,697 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Alnylam Pharmaceuticals by 3.3% in the second quarter. Geode Capital Management LLC now owns 2,398,770 shares of the biopharmaceutical company’s stock valued at $779,857,000 after purchasing an additional 75,936 shares during the period. Finally, Orbis Allan Gray Ltd lifted its stake in shares of Alnylam Pharmaceuticals by 29.8% in the second quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock worth $691,771,000 after buying an additional 486,489 shares during the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the company. Weiss Ratings raised Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Thursday. Stifel Nicolaus lifted their target price on shares of Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the stock a “buy” rating in a research report on Thursday, December 11th. Needham & Company LLC upped their price target on shares of Alnylam Pharmaceuticals from $520.00 to $529.00 and gave the company a “buy” rating in a research report on Monday, January 12th. Jefferies Financial Group lowered their price objective on shares of Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating on the stock in a research report on Thursday, October 30th. Finally, Barclays boosted their target price on shares of Alnylam Pharmaceuticals from $460.00 to $527.00 and gave the company an “overweight” rating in a research note on Friday, October 31st. Twenty-two equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $490.96.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.